Novo Nordisk Takes Wegovy Pill Weight-Loss Drug Off the Shots and onto the Tablets
The Danish pharmaceutical giant Novo Nordisk has made a significant breakthrough in the weight-loss medication market by launching the pill version of its popular drug, Wegovy. This move marks the first time a GLP-1 weight-loss medication has been approved in pill form, paving the way for other drugs to follow suit.
As of now, starter doses of Wegovy are available at pharmacies with a prescription, and stronger doses are expected to hit the market by the end of the week. The FDA-approved pill, containing semaglutide, the same active ingredient as Ozempic, has been shown to promote weight loss and reduce the risk of cardiovascular events in adults who are overweight or obese.
Patients will need to take the pill daily on an empty stomach with a small amount of water and avoid eating, drinking, or taking other medications for 30 minutes afterward. The starter dose is 1.5mg, but the pill will also be available in doses of 4mg, 9mg, and 25mg.
Healthcare professionals typically increase patients' dosages every 30 days until the maximum is reached. Novo Nordisk's senior vice president for marketing and patient solutions, Ed Cinca, believes that this pill form will make it possible for more people to achieve their weight-loss goals and lower the risks of cardiovascular disease.
The commercial cost of Wegovy pills is significantly lower than the standard injection, with commercially-insured people paying as little as $25 per month. For those paying out-of-pocket, the monthly cost ranges from $149 to $299. This move aims to make the medication more accessible to those who need it.
Wegovy's pill version has shown promising results in clinical trials, including an average weight loss of 17% over 64 weeks and a reduced risk of cardiovascular events. Eli Lilly is also working on its own GLP-1 drug, forglipron, which is expected to be approved by this summer. However, preliminary results from the company's trial have shown that the pill may not have the same restrictions as Wegovy's pill.
As the weight-loss medication market continues to evolve, the introduction of Wegovy pills marks a significant development in addressing obesity and related health issues. With its affordability and accessibility, Novo Nordisk's pill version is poised to become a game-changer for those seeking to lose weight and improve their overall health.
The Danish pharmaceutical giant Novo Nordisk has made a significant breakthrough in the weight-loss medication market by launching the pill version of its popular drug, Wegovy. This move marks the first time a GLP-1 weight-loss medication has been approved in pill form, paving the way for other drugs to follow suit.
As of now, starter doses of Wegovy are available at pharmacies with a prescription, and stronger doses are expected to hit the market by the end of the week. The FDA-approved pill, containing semaglutide, the same active ingredient as Ozempic, has been shown to promote weight loss and reduce the risk of cardiovascular events in adults who are overweight or obese.
Patients will need to take the pill daily on an empty stomach with a small amount of water and avoid eating, drinking, or taking other medications for 30 minutes afterward. The starter dose is 1.5mg, but the pill will also be available in doses of 4mg, 9mg, and 25mg.
Healthcare professionals typically increase patients' dosages every 30 days until the maximum is reached. Novo Nordisk's senior vice president for marketing and patient solutions, Ed Cinca, believes that this pill form will make it possible for more people to achieve their weight-loss goals and lower the risks of cardiovascular disease.
The commercial cost of Wegovy pills is significantly lower than the standard injection, with commercially-insured people paying as little as $25 per month. For those paying out-of-pocket, the monthly cost ranges from $149 to $299. This move aims to make the medication more accessible to those who need it.
Wegovy's pill version has shown promising results in clinical trials, including an average weight loss of 17% over 64 weeks and a reduced risk of cardiovascular events. Eli Lilly is also working on its own GLP-1 drug, forglipron, which is expected to be approved by this summer. However, preliminary results from the company's trial have shown that the pill may not have the same restrictions as Wegovy's pill.
As the weight-loss medication market continues to evolve, the introduction of Wegovy pills marks a significant development in addressing obesity and related health issues. With its affordability and accessibility, Novo Nordisk's pill version is poised to become a game-changer for those seeking to lose weight and improve their overall health.
. I think it's amazing that the pharmaceutical giant Novo Nordisk is making it easier for people to access weight loss medication without having to deal with daily injections 
. The fact that the pill version is more affordable and accessible, especially for commercially-insured folks, is a total win in my book 
. I mean, we all know how hard it can be to stick to a diet or exercise routine when you're struggling with weight-related health issues 
. So, this new pill form could be the game-changer many people have been waiting for 
. Plus, the results from clinical trials are pretty impressive - 17% weight loss over 64 weeks? That's like, totally life-changing! 
I just hope it encourages more people to take control of their health and make those lifestyle changes that can lead to a healthier, happier life 
.
I mean, who wouldn't want to take a pill instead of getting shots? 
It makes total sense that the cost is lower too, $25 a month for insured people, that's crazy affordable! 
But what really gets me thinking is how much it's going to change the game for obesity and health issues. I mean, 17% weight loss in 64 weeks is insane! 
Does that make a difference? And what about all those people who are waiting for Eli Lilly's drug to come out? Are they going to get left behind? 
so hyped! i mean, who doesn't want to take a pill instead of getting shots every month? plus, the prices are pretty reasonable, that's a big win for people struggling with weight issues 
]
]
]
]
]
. $25 a month is insane low for ppl with insurance, that's like a free lunch lol. and it's not just about lose weight, it's about reducing cardiovascular risks too, which is a huge deal. I'm loving this development, can't wait to see more GLP-1 meds on the market 
. The fact that Wegovy pills have shown such promising results in clinical trials gives me confidence that they'll make a real difference for people.
. i remember my aunt trying to lose weight a few years ago and she had to take some kinda medication for a year or something. can you imagine having to do that every day? 
anyway, the prices seem pretty affordable though, like $25 a month? that's nothing compared to what they charge for ozempic shots 
! People can finally just take one pill a day and be on their way to losing that extra weight 
! This is gonna be huge for obesity awareness and getting people on track with their health goals 
Wegovy pills are finally here and it's a GAME CHANGER! I mean, who doesn't want to lose a little weight or just feel more comfortable in their own skin? And the best part is that Novo Nordisk has made this medication more accessible to people with commercially-insured plans - $25 a month is NOT BAD AT ALL! 
! This means that people who are struggling with obesity can now take a daily pill instead of getting shots 
. Now we just have to wait and see how the Eli Lilly pill version works out... fingers crossed it's as effective! 
. But seriously though, it's awesome that Novo Nordisk is making Wegovy more accessible to people. The prices are still a bit steep for me, but $25 a month is basically pennies compared to what I've been paying out-of-pocket 
. Kidding aside, it's great that Eli Lilly is working on its own GLP-1 drug. We need more options in the market! This pill version is definitely going to make a difference for people struggling with obesity and related health issues